November 3rd, 2026Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ESMO 2026See what leading breast oncologists have to say about practice-informing data to come out of the 2026 ESMO Congress.Read more
November 2nd, 2026Camizestrant Approval Paves the Way for ctDNA-Guided Switching in Emergent ESR1-Mutated HR+/HER2– Advanced Breast CancerErica L. Mayer, MD, MPH, discusses the FDA approval of camizestrant for ESR1-mutated HR+/HER2– breast cancer and the importance of ctDNA monitoring.Read more
October 29th, 2026Key Questions on ADC Selection, Sequencing, and Toxicity Management Across Breast Cancer SubtypesBreast cancer experts answer key questions on selecting, sequencing, and managing ADCs in HR-positive, HER2-positive, and triple-negative disease.Read more